<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526224</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002359</org_study_id>
    <nct_id>NCT03526224</nct_id>
  </id_info>
  <brief_title>Teriflunomide Tecfidera LMCE</brief_title>
  <official_title>Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of teriflunomide in reducing cortical gray matter&#xD;
      (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl&#xD;
      fumarate (Tecfidera®)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Actual">July 10, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in CGM between teriflunomide and dimethyl fumarate</measure>
    <time_frame>24 months</time_frame>
    <description>Percent change in cortical gray matter (CGM) between those on teriflunomide and dimethyl fumarate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LM CE lesions at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of leptomeningeal (LM) lesions as measured by presence (number) of LM contrast enhancing (CE) lesions foci on three-dimensional fluid-attenuated-inversion recovery (3D_FLAIR) MRI performed 10 minutes post-contrast injection between those on teriflunomide and dimethyl fumarate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CGM atrophy and LM inflammation</measure>
    <time_frame>24 months</time_frame>
    <description>Association between the development of CGM atrophy and LM inflammation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Tecfidera</condition>
  <condition>Teriflunomide</condition>
  <arm_group>
    <arm_group_label>Aubagio</arm_group_label>
    <description>Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tecfidera</arm_group_label>
    <description>Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimethyl Fumarate</intervention_name>
    <description>Individuals with MS treated with dimethyl fumarate (Tecfidera)</description>
    <arm_group_label>Tecfidera</arm_group_label>
    <other_name>Tecfidera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide</intervention_name>
    <description>Individuals with MS treated with teriflunomide (Aubagio)</description>
    <arm_group_label>Aubagio</arm_group_label>
    <other_name>Aubagio</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals diagnosed with MS who have used dimethyl fumarate or teriflunomide and had&#xD;
        magnetic resonance imaging at baseline (before starting disease modifying therapy (DMT) in&#xD;
        question), 12 months after starting DMT, and 24 months after starting DMT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with MS according to McDonald criteria&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Relapsing disease course&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score of ≤ 5.5&#xD;
&#xD;
          -  MRI obtained at baseline (medication start date), 12 months, and 24 months&#xD;
&#xD;
          -  Treated with 14mg of teriflunomide ≥ 3 months or with 240mg of dimethyl fumarate ≥ 3&#xD;
             months to meet inclusion, reflective of recommended dosing on the package label&#xD;
&#xD;
          -  Clinical information available over the 24 month follow-up&#xD;
&#xD;
          -  None of the exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of non-relapsing MS&#xD;
&#xD;
          -  Use of experimental drug or investigational procedure during the study period&#xD;
&#xD;
          -  Pregnancy during study period&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Relapse within 30 days prior to any of the 3 MRIs&#xD;
&#xD;
          -  Corticosteroid use within 30 days prior to the MRIs&#xD;
&#xD;
          -  Teriflunomide patients who have used leflunomide&#xD;
&#xD;
          -  Pre-baseline use of alemtuzumab, cladribine, rituximab, or mitoxantrone&#xD;
&#xD;
          -  Any other factor that, in the opinion of the investigator, would make the subject&#xD;
             unsuitable for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Buffalo Neuroimaging Analysis Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B. Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.</citation>
    <PMID>30870983</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Robert Zivadinov, MD, PhD</investigator_full_name>
    <investigator_title>Director, Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriflunomide</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

